VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB (ABSK021) GRANTED FAST TRACK
DESIGNATION BY U.S. FDA
06
2023-12
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
04
2023-12
Announcements and Notices
INSIDE INFORMATION - ABBISKO REACHED A LICENSE AGREEMENT WITH MERCK
FOR PIMICOTINIB (ABSK021)
28
2023-11
Announcements and Notices
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF
PIMICOTINIB (ABSK021) IN THE TREATMENT OF ADVANCED
PANCREATIC CANCER IN CHINA
09
2023-11
Announcements and Notices
VOLUNTARY ANNOUNCEMENT - CD73 INHIBITOR ABSK051 OBTAINED IND APPROVAL FROM NMPA
08
2023-11
Announcements and Notices
VOLUNTARY ANNOUNCEMENT - FGFR4 MUTANT INHIBITOR
ABSK012 OBTAINED CLINICAL STUDY APPROVAL FROM U.S. FDA
03
2023-11
Announcements and Notices
VOLUNTARY ANNOUNCEMENT - CLINICAL UPDATES OF PIMICOTINIB (ABSK021) PRESENTED AT THE 2023 CTOS ANNUAL MEETING
01
2023-11
Monthly Returns
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
30
2023-10
Announcements and Notices
VOLUNTARY ANNOUNCEMENT -
TWO MAJOR CLINICAL UPDATES OF PIMICOTINIB (ABSK021)
WILL BE PRESENTED AT THE 2023 CTOS ANNUAL MEETING
27
2023-10
Announcements and Notices
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY NMPA OBTAINED FOR ABSK112
